Trial Profile
Baricitinib in Relapsing Giant Cell Arteritis (GCA): A Phase II, Single-institution, Open-label Pilot Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Giant cell arteritis
- Focus Adverse reactions; Proof of concept
- 12 Feb 2022 Results published in the Annals of the Rheumatic Diseases
- 09 Nov 2021 Results presented at the ACR Convergence 2021
- 29 Jun 2021 Status changed from active, no longer recruiting to completed.